Recently, a variety of novel biomarkers such as PITX2 methylation and C1GALT1 autoantibody that forecast prognosis, and B7-H3 that predicts immunotherapeutic prognosis and reaction in HNSCC were identified gradually [37–39]. This evidence concerns the gene PITX2 and head and neck squamous cell carcinoma.